Intrexon, its wholly-owned subsidiary Precigen and Merck have been working together since 2015 on CAR-T, with the German firm’s Merck Serono division ... out in front with products on the ...

At the forthcoming Pharmaccess Leaders Forum Spring conference, Ana Céspedes, senior vice president of global marketing and strategy at EMD Serono, a business of Merck KGaA, Darmstadt ...

Merck KGaA’s U.S. pharma arm has recruited actor Selma Blair for a collaboration around multiple sclerosis treatment Mavenclad. | No cruel intentions here: Merck KGaA’s U.S. pharma arm has recruited ...

Merck & Co. has penned a $300 million biobucks-per-product deal with cancer biotech Epitopea to identify previously secret ...

The growing demand for immune checkpoint inhibitors is mainly driven by the rising incidence of lung cancer, the increasing prevalence of melanoma, and the expanding number of research studies related ...

The FDA has authorized ImmunityBio’s expanded access program to bring alternative sources of the cancer-fighting bacteria BCG ...

Merck & Co., Inc. operates as a healthcare company ... The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions.

In this article, we are going to take a look at where Merck & Co., Inc. (NYSE:MRK) stands against other most oversold S&P 500 stocks in 2024. Strong economic growth and the prospect of declining ...

Following the non-adoption of key financial delegations at the Combined General Meeting held on February 11, 2025, the Company is facing an uncertain and adverse situation regarding the continuation ...